<suk class="evrhnz"></suk>

evo视讯生物

Be the most trusted biotech company

2022-10-28

The Phase 2 IND Application of Henlius’ Novel Anti-HER2 mAb HLX22 Combined with Anti-PD-1 mAb HANSIZHUANG and HANQUYOU for the Treatment of HER2+ Gastric Cancer Approved by NMPA
2022-10-27

Phase 2 Study of the PD-1 Inhibitor Serplulimab in Patients with MSI-H Solid Tumours Published in British Journal of Cancer
2022-10-25

Henlius Anti-PD-1 mAb Serplulimab Combined with Chemotherapy and Concurrent Radiotherapy MRCT Phase 3 Study on First-Line LS-SCLC Patients Received Clinical Trial Approved in Australia
2022-10-17

The IND Application of Henlius’ Novel Anti-GARP mAb HLX60 Approved by NMPA
2022-09-30

Henlius completed the phase 1 clinical trial of HLX22 for the treatment of HER2 overexpressing advanced solid tumours
2022-09-29

Henlius Received IND Approval from US FDA for HLX07 in CSCC patients
2022-09-28

ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world
2022-09-08

Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HANBEITAI in Patients with Advanced Hepatocellular Carcinoma Published in Liver Cancer
2022-08-26

Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy Received Clinical Trial Approval in Australia